Drug Type Small molecule drug |
Synonyms 8-chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Estazolam (JP17/USP/INN), A-47631 + [9] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (25 Apr 1975), |
Regulation- |
Molecular FormulaC16H11ClN4 |
InChIKeyCDCHDCWJMGXXRH-UHFFFAOYSA-N |
CAS Registry29975-16-4 |
Start Date01 Apr 2026 |
Sponsor / Collaborator |
Start Date07 Jan 2026 |
Sponsor / Collaborator |
Start Date27 Nov 2025 |
Sponsor / Collaborator |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Anxiety Disorders | China | 01 Jan 1981 | |
| Epilepsy | China | 01 Jan 1981 | |
| Sleep Initiation and Maintenance Disorders | Japan | 25 Apr 1975 | |
| Sleep Initiation and Maintenance Disorders | Japan | 25 Apr 1975 |
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 4 | 30 | benzodiazepine | heymgutvxx = mecxpqcojk isizmjpcbv (mhphmskyjf, edqgrrwuov - xdyriazdum) View more | - | 26 Mar 2012 |






